Expression Therapeutics

GA - TuckerBiotechnology1 H-1B visas (FY2023)

Focus: Expression Therapeutics is a publicly-traded gene therapy biotech focused on immunology, rare diseases, and gastroenterology, headquartered in Tucker, Georgia. The company operates at early-stage development with a modest pipeline spanning Phase 1 to Phase 2 programs.

Immunology Rare Diseases Gastroenterology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Expression Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Expression Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Infliximab

RheumatoId Arthritis

N/A

Clinical Trials (1)

NCT03016260RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis

N/A

Help build intelligence for Expression Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage gene therapy focus in high-value therapeutic areas (immunology, rare diseases) with significant long-term upside potential
Public company status provides liquidity and potential equity upside without typical early-stage startup burn risk
Demonstrated willingness to sponsor H1B visas (1 approval, 0 denials in 2023) suggests openness to global talent acquisition

Watch Out For

Zero active job openings at time of data capture indicates minimal near-term hiring or potential organizational contraction
Pipeline is extremely early-stage with only 1 Phase 1 program and 1 Phase 2 program; no Phase 3 or marketed products, meaning 10+ years to potential commercial success
Limited public visibility: no recent news, publications, or financial data provided suggests either early-stage stealth mode or lack of market momentum

Generated by Claude from Expression Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT01299545Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

N/A

Gene therapy

Hemophilia A

PHASE_1

Clinical Trials (1)

NCT04418414Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A

Phase 1

Gradual immunosuppression drug withdrawal

Liver Transplantation

PHASE_2

Clinical Trials (1)

NCT00647283Assessment Of the Safety and Benefit of Prospective Immunosuppressive Drug Withdrawal in Liver Transplantation and Prediction of Operational Tolerance

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 4 clinical trials

Top TAs: Immunology, Gastroenterology, Rare Diseases

H-1B (2023): 1 approval

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Immunology

2 pipeline

Gastroenterology

1 pipeline

Rare Diseases

1 pipeline

Marketed

Pipeline

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub